Legislation introduced by Senators Chuck Grassley (Republican – Iowa) and Patrick Leahy (Democrat – Vermont) to protect whistleblowers who shine a light on unlawful anticompetitive activities passed unanimously in the Senate on October 18. The Criminal Antitrust Anti-Retaliation Act prohibits reprisal against private sector employees who provide information to the Department of Justice regarding conduct that violates the criminal antitrust laws.
“Competition is essential to a thriving, affordable and innovative marketplace. When our antitrust laws are violated, consumers are often left paying the price. The Criminal Antitrust Anti-Retaliation Act, which passed today in the US Senate, encourages private sector employees to blow the whistle on activities that violate our antitrust laws and harm consumers. This bill also protects these private sector employees from reprisal in the workplace after coming forward with information working to protect whistleblowers, specifically in the private sector,” Grassley said.
“The Senate has once again come together to protect those who step forward to report criminal antitrust violations, such as price fixing. Since our nation’s founding, our country has a proud history of working to protect whistleblowers, who often take on significant personal and professional risks to report fraud, abuse, and criminal activity. More work remains but I am hopeful the House will take up and pass this important legislation without delay,” Leahy said.The Criminal Antitrust Anti-Retaliation Act extends whistleblower protections for employees who provide information to the Department of Justice related to criminal antitrust violations. The Senate unanimously passed a similar version of the legislation in 2013, 2015, and 2017.
Full Content: Chuck Grassley
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas